{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:57:59Z","timestamp":1793908679443,"version":"4.8.0"},"reference-count":217,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008235","name":"School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.pharmthera.2017.05.011","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T07:33:01Z","timestamp":1495524781000},"page":"142-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":189,"special_numbering":"C","title":["Targeting nuclear receptors for the treatment of fatty liver disease"],"prefix":"10.1016","volume":"179","author":[{"given":"Naoki","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shioko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","article-title":"Pleiotropic roles of bile acids in metabolism","volume":"17","author":"de Aguiar Vallim","year":"2013","journal-title":"Cell Metabolism"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPAR\u03b3 signaling and metabolism: The good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nature Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2017.05.011_bb0015","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1007\/s10620-014-3289-x","article-title":"Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease","volume":"59","author":"Ahn","year":"2014","journal-title":"Digestive Diseases and Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0020","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.bcp.2007.05.027","article-title":"13-Oxo-ODE is an endogenous ligand for PPARgamma in human colonic epithelial cells","volume":"74","author":"Altmann","year":"2007","journal-title":"Biochemical Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0025","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1124\/mol.104.005496","article-title":"Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor, and liver X receptor in mouse liver","volume":"66","author":"Anderson","year":"2004","journal-title":"Molecular Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.pharmthera.2017.05.011_bb0035","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1074\/jbc.273.10.5678","article-title":"Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha)","volume":"273","author":"Aoyama","year":"1998","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12272-010-0313-3","article-title":"Selective inhibition of activated stellate cells and protection from carbon tetrachloride-induced liver injury in rats by a new PPARgamma agonist KR62776","volume":"33","author":"Bae","year":"2010","journal-title":"Archives of Pharmacal Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0045","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.drudis.2014.11.011","article-title":"Targeting xenobiotic receptors PXR and CAR in human diseases","volume":"20","author":"Banerjee","year":"2015","journal-title":"Drug Discovery Today"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0050","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1210\/en.2010-1468","article-title":"The PPAR\u03b2\/\u03b4 activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1\u03b1-Lipin 1-PPAR\u03b1 pathway leading to increased fatty acid oxidation","volume":"152","author":"Barroso","year":"2011","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0055","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1124\/dmd.108.023317","article-title":"Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice","volume":"37","author":"Beilke","year":"2009","journal-title":"Drug Metabolism and Disposition"},{"issue":"11","key":"10.1016\/j.pharmthera.2017.05.011_bb0060","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s00204-014-1348-x","article-title":"Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms","volume":"89","author":"Bitter","year":"2015","journal-title":"Archives of Toxicology"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0065","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1053\/j.gastro.2016.12.037","article-title":"Intestinal farnesoid X receptor controls transintestinal cholesterol excretion in mice","volume":"152","author":"de Boer","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cmet.2007.06.010","article-title":"PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties","volume":"6","author":"Bouhlel","year":"2007","journal-title":"Cell Metabolism"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0075","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/toxsci\/kfr075","article-title":"Transgenic animal models in toxicology: Historical perspectives and future outlook","volume":"121","author":"Boverhof","year":"2011","journal-title":"Toxicological Sciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0080","doi-asserted-by":"crossref","first-page":"G283","DOI":"10.1152\/ajpgi.00205.2016","article-title":"Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from non-parenchymal cells","volume":"312","author":"Brocker","year":"2017","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"issue":"8","key":"10.1016\/j.pharmthera.2017.05.011_bb0085","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"40","key":"10.1016\/j.pharmthera.2017.05.011_bb0090","doi-asserted-by":"crossref","first-page":"42530","DOI":"10.18632\/oncotarget.6466","article-title":"Oleoylethanolamide, an endogenous PPAR-\u03b1 ligand, attenuates liver fibrosis targeting hepatic stellate cells","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0095","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/toxsci\/kfs211","article-title":"Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice","volume":"129","author":"Cheng","year":"2012","journal-title":"Toxicological Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.tips.2012.03.003","article-title":"Pregnane X receptor as a target for treatment of inflammatory bowel disorders","volume":"33","author":"Cheng","year":"2012","journal-title":"Trends in Pharmacological Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0105","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/jpet.110.170225","article-title":"Therapeutic role of rifaximin in inflammatory bowel disease: Clinical implication of human pregnane X receptor activation","volume":"335","author":"Cheng","year":"2010","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"6037","key":"10.1016\/j.pharmthera.2017.05.011_bb0110","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.1204265","article-title":"Human fatty liver disease: Old questions and new insights","volume":"332","author":"Cohen","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408444.2013.835784","article-title":"Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPAR\u03b1) as a case study","volume":"44","author":"Corton","year":"2014","journal-title":"Critical Reviews in Toxicology"},{"issue":"36","key":"10.1016\/j.pharmthera.2017.05.011_bb0120","doi-asserted-by":"crossref","first-page":"28240","DOI":"10.1074\/jbc.M003337200","article-title":"Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor\/retinoid X receptor","volume":"275","author":"Costet","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0125","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Annals of Internal Medicine"},{"issue":"30","key":"10.1016\/j.pharmthera.2017.05.011_bb0130","doi-asserted-by":"crossref","first-page":"25123","DOI":"10.1074\/jbc.M112.375907","article-title":"Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21","volume":"287","author":"Cyphert","year":"2012","journal-title":"The Journal of Biological Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0135","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: A tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/hep.27274","article-title":"Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation","volume":"61","author":"Degirolamo","year":"2015","journal-title":"Hepatology"},{"issue":"45","key":"10.1016\/j.pharmthera.2017.05.011_bb0145","doi-asserted-by":"crossref","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","article-title":"Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1","volume":"274","author":"Delerive","year":"1999","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0150","first-page":"1029","article-title":"DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha","volume":"16","author":"Delerive","year":"2002","journal-title":"Molecular Endocrinology"},{"issue":"47","key":"10.1016\/j.pharmthera.2017.05.011_bb0155","doi-asserted-by":"crossref","first-page":"36703","DOI":"10.1074\/jbc.M004045200","article-title":"Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators","volume":"275","author":"Delerive","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.05.011_bb0160","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/751859","article-title":"Coordinated actions of FXR and LXR in metabolism: From pathogenesis to pharmacological targets for type 2 diabetes","volume":"2014","author":"Ding","year":"2014","journal-title":"International Journal of Endocrinology"},{"issue":"44","key":"10.1016\/j.pharmthera.2017.05.011_bb0165","doi-asserted-by":"crossref","first-page":"18831","DOI":"10.1073\/pnas.0909731106","article-title":"Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease","volume":"106","author":"Dong","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0170","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00535-012-0533-z","article-title":"Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: A multicenter large retrospective study","volume":"47","author":"Eguchi","year":"2012","journal-title":"Journal of Gastroenterology"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0175","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0180","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1124\/jpet.102.047217","article-title":"Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone","volume":"306","author":"Enomoto","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0185","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cell.2014.03.012","article-title":"Nuclear receptors, RXR, and the big bang","volume":"157","author":"Evans","year":"2014","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0190","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0195","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s00204-016-1877-6","article-title":"Role of the lipid-regulated NF-\u03baB\/IL-6\/STAT3 axis in alpha-naphthyl isothiocyanate-induced liver injury","volume":"91","author":"Fang","year":"2017","journal-title":"Archives of Toxicology"},{"issue":"24","key":"10.1016\/j.pharmthera.2017.05.011_bb0200","doi-asserted-by":"crossref","first-page":"21466","DOI":"10.1074\/jbc.M110.209973","article-title":"Human SREBP1c expression in liver is directly regulated by peroxisome proliferator-activated receptor alpha (PPARalpha)","volume":"286","author":"Fern\u00e1ndez-Alvarez","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0205","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","article-title":"A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease","volume":"40","author":"Fern\u00e1ndez-Miranda","year":"2008","journal-title":"Digestive and Liver Disease"},{"issue":"10","key":"10.1016\/j.pharmthera.2017.05.011_bb0210","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metabolism and Disposition"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0215","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0220","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0225","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1210\/en.2003-1671","article-title":"Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes","volume":"145","author":"Fu","year":"2004","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.pharmthera.2017.05.011_bb0230","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/hepr.12649","article-title":"Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis","volume":"46","author":"Fujimori","year":"2016","journal-title":"Hepatology Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2017.05.011_bb0235","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1872-034X.2009.00509.x","article-title":"Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization","volume":"39","author":"Fukushima","year":"2009","journal-title":"Hepatology Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2017.05.011_bb0240","first-page":"5011","article-title":"Effects of the hepatocarcinogen nafenopin, a peroxisome proliferator, on the activities of rat liver glutathione-requiring enzymes and catalase in comparison to the action of phenobarbital","volume":"45","author":"Furukawa","year":"1985","journal-title":"Cancer Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0245","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metabolism"},{"issue":"38","key":"10.1016\/j.pharmthera.2017.05.011_bb0250","doi-asserted-by":"crossref","first-page":"25984","DOI":"10.1074\/jbc.M109.016808","article-title":"The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity","volume":"284","author":"Gao","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0255","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.plipres.2008.04.002","article-title":"Sterol regulators of cholesterol homeostasis and beyond: The oxysterol hypothesis revisited and revised","volume":"47","author":"Gill","year":"2008","journal-title":"Progress in Lipid Research"},{"key":"10.1016\/j.pharmthera.2017.05.011_bb0260","doi-asserted-by":"crossref","first-page":"10713","DOI":"10.1038\/ncomms10713","article-title":"Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis","volume":"7","author":"Gomez-Ospina","year":"2016","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0265","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","article-title":"An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease","volume":"151","author":"Gonzalez","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0270","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.tox.2007.09.030","article-title":"PPARalpha: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators","volume":"246","author":"Gonzalez","year":"2008","journal-title":"Toxicology"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0275","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.tox.2013.07.002","article-title":"PPAR\u03b2\/\u03b4 modulates ethanol-induced hepatic effects by decreasing pyridoxal kinase activity","volume":"311","author":"Goudarzi","year":"2013","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0280","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molmet.2015.01.009","article-title":"The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis","volume":"4","author":"Griffett","year":"2015","journal-title":"Molecular Metabolism"},{"issue":"12","key":"10.1016\/j.pharmthera.2017.05.011_bb0285","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1124\/dmd.111.041012","article-title":"Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease","volume":"39","author":"Hardwick","year":"2011","journal-title":"Drug Metabolism and Disposition"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0290","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cmet.2013.11.018","article-title":"Regulation of steatohepatitis and PPAR\u03b3 signaling by distinct AP-1 dimers","volume":"19","author":"Hasenfuss","year":"2014","journal-title":"Cell Metabolism"},{"issue":"37","key":"10.1016\/j.pharmthera.2017.05.011_bb0295","doi-asserted-by":"crossref","first-page":"28918","DOI":"10.1074\/jbc.M910350199","article-title":"Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting","volume":"275","author":"Hashimoto","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0300","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/hepr.12333","article-title":"Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges","volume":"45","author":"Hashimoto","year":"2015","journal-title":"Hepatology Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2017.05.011_bb0305","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00535-010-0277-6","article-title":"Accurate and simple method for quantification of hepatic fat content using magnetic resonance imaging: A prospective study in biopsy-proven nonalcoholic fatty liver disease","volume":"45","author":"Hatta","year":"2010","journal-title":"Journal of Gastroenterology"},{"issue":"8","key":"10.1016\/j.pharmthera.2017.05.011_bb0310","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1210\/jc.2013-4427","article-title":"Metabolically healthy obesity, presence or absence of fatty liver, and risk of type 2 diabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 20 (TOPICS 20)","volume":"99","author":"Heianza","year":"2014","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0315","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrd4280","article-title":"Liver X receptors in lipid metabolism: Opportunities for drug discovery","volume":"13","author":"Hong","year":"2014","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2017.05.011_bb0320","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1038\/srep06437","article-title":"Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor","volume":"4","author":"Hsu","year":"2014","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2017.05.011_bb0325","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jnutbio.2016.09.015","article-title":"PPAR\u03b1 protects against trans-fatty-acid-containing diet-induced steatohepatitis","volume":"39","author":"Hu","year":"2017","journal-title":"The Journal of Nutritional Biochemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0330","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.20280","article-title":"Beyond insulin resistance in NASH: TNF-alpha or adiponectin?","volume":"40","author":"Hui","year":"2004","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0335","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jhep.2016.01.016","article-title":"Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid","volume":"64","author":"Ijssennagger","year":"2016","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0340","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21","volume":"5","author":"Inagaki","year":"2007","journal-title":"Cell Metabolism"},{"issue":"10","key":"10.1016\/j.pharmthera.2017.05.011_bb0345","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6294","key":"10.1016\/j.pharmthera.2017.05.011_bb0350","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","article-title":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators","volume":"347","author":"Issemann","year":"1990","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.pharmthera.2017.05.011_bb0355","doi-asserted-by":"crossref","first-page":"E1369","DOI":"10.1073\/pnas.1202464109","article-title":"Protection from liver fibrosis by a peroxisome proliferator-activated receptor \u03b4 agonist","volume":"109","author":"Iwaisako","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0360","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.05.011_bb0365","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nature Communications"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0370","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jhep.2007.03.020","article-title":"Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model","volume":"47","author":"Kamada","year":"2007","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0375","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/liv.12089","article-title":"The impact of hepatic steatosis on liver regeneration after partial hepatectomy","volume":"33","author":"Kele","year":"2013","journal-title":"Liver International"},{"issue":"42","key":"10.1016\/j.pharmthera.2017.05.011_bb0380","doi-asserted-by":"crossref","first-page":"39438","DOI":"10.1074\/jbc.M105863200","article-title":"Characterization of the human ABCG1 gene: Liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein","volume":"276","author":"Kennedy","year":"2001","journal-title":"The Journal of Biological Chemistry"},{"issue":"11","key":"10.1016\/j.pharmthera.2017.05.011_bb0385","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1172\/JCI6223","article-title":"Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting","volume":"103","author":"Kersten","year":"1999","journal-title":"The Journal of Clinical Investigation"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0390","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ccell.2016.10.007","article-title":"Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis","volume":"30","author":"Kettner","year":"2016","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0395","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.molmet.2013.12.003","article-title":"Inventing new medicines: The FGF21 story","volume":"3","author":"Kharitonenkov","year":"2013","journal-title":"Molecular Metabolism"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0400","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0405","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0410","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/hep.26699","article-title":"All-trans-retinoic acid ameliorates hepatic steatosis in mice by a novel transcriptional cascade","volume":"59","author":"Kim","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0415","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/carcin\/bgl249","article-title":"Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice","volume":"28","author":"Kim","year":"2007","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0420","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/hep.26683","article-title":"Hepatic oxidative stress activates the Gadd45b gene by way of degradation of the transcriptional repressor STAT3","volume":"59","author":"Kim","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0425","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/hepr.12762","article-title":"Clinicopathological characteristics of non-B non-C hepatocellular carcinoma without past HBV infection","volume":"47","author":"Kimura","year":"2017","journal-title":"Hepatology Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0430","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3748\/wjg.v23.i4.712","article-title":"Association between endotoxemia and histological features of nonalcoholic fatty liver disease","volume":"23","author":"Kitabatake","year":"2017","journal-title":"World Journal of Gastroenterology"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.109.002014","article-title":"Xenobiotic, bile acid, and cholesterol transporters: Function and regulation","volume":"62","author":"Klaassen","year":"2010","journal-title":"Pharmacological Reviews"},{"issue":"15","key":"10.1016\/j.pharmthera.2017.05.011_bb0440","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.1073\/pnas.91.15.7355","article-title":"Differential expression and activation of a family of murine peroxisome proliferator-activated receptors","volume":"91","author":"Kliewer","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0445","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1210\/er.2001-0038","article-title":"The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism","volume":"23","author":"Kliewer","year":"2002","journal-title":"Endocrine Reviews"},{"issue":"7","key":"10.1016\/j.pharmthera.2017.05.011_bb0450","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00204-015-1522-9","article-title":"Regulation of gene expression by CAR: An update","volume":"89","author":"Kobayashi","year":"2015","journal-title":"Archives of Toxicology"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0455","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/9667","article-title":"The gene mutated in adult-onset type II citrullinaemia encodes a putative mitochondrial carrier protein","volume":"22","author":"Kobayashi","year":"1999","journal-title":"Nature Genetics"},{"issue":"10","key":"10.1016\/j.pharmthera.2017.05.011_bb0460","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00535-003-1178-8","article-title":"Increase in the prevalence of fatty liver in Japan over the past 12years: Analysis of clinical background","volume":"38","author":"Kojima","year":"2003","journal-title":"Journal of Gastroenterology"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0465","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbadis.2014.12.011","article-title":"Steatogenesis in adult-onset type II citrullinemia is associated with down-regulation of PPAR\u03b1","volume":"1852","author":"Komatsu","year":"2015","journal-title":"Biochimica et Biophysica Acta"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0470","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2008.05.016","article-title":"Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease","volume":"49","author":"Komatsu","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0475","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/2045-3701-2-34","article-title":"GW501516-activated PPAR\u03b2\/\u03b4 promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation","volume":"2","author":"Kostadinova","year":"2012","journal-title":"Cell & Bioscience"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0480","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.510230624","article-title":"Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study","volume":"23","author":"Laurin","year":"1996","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.pharmthera.2017.05.011_bb0485","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1073\/pnas.0511253103","article-title":"PPARdelta regulates glucose metabolism and insulin sensitivity","volume":"103","author":"Lee","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0490","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1128\/MCB.15.6.3012","article-title":"Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators","volume":"15","author":"Lee","year":"1995","journal-title":"Molecular and Cellular Biology"},{"issue":"12","key":"10.1016\/j.pharmthera.2017.05.011_bb0495","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/hepr.12244","article-title":"Hepatic molecular effects of rosiglitazone in human non-alcoholic steatohepatitis suggest long-term pro-inflammatory damage","volume":"44","author":"Lemoine","year":"2014","journal-title":"Hepatology Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0500","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/toxsci\/kfw127","article-title":"Editor's highlight: Neonatal activation of the xenobiotic-sensors PXR and CAR results in acute and persistent down-regulation of PPAR\u03b1-signaling in mouse liver","volume":"153","author":"Li","year":"2016","journal-title":"Toxicological Sciences"},{"issue":"11","key":"10.1016\/j.pharmthera.2017.05.011_bb0505","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.bcp.2013.08.015","article-title":"Bile acid receptors in non-alcoholic fatty liver disease","volume":"86","author":"Li","year":"2013","journal-title":"Biochemical Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0510","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1124\/mol.114.097287","article-title":"SLC13A5 is a novel transcriptional target of the pregnane X receptor and sensitizes drug-induced steatosis in human liver","volume":"87","author":"Li","year":"2015","journal-title":"Molecular Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0515","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/jbmr.2936","article-title":"FGF21 is not a major mediator for bone homeostasis or metabolic actions of PPAR\u03b1 and PPAR\u03b3 agonists","volume":"32","author":"Li","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2017.05.011_bb0520","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cbi.2014.03.014","article-title":"The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice","volume":"217","author":"L\u00edvero","year":"2014","journal-title":"Chemico-Biological Interactions"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0525","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1053\/j.gastro.2015.06.016","article-title":"The hierarchical model of NAFLD: Prognostic significance of histologic features in NASH","volume":"149","author":"Loomba","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0530","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nm.2332","article-title":"Brain PPAR-\u03b3 promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones","volume":"17","author":"Lu","year":"2011","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0535","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1756283X16663396","article-title":"Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: Evidence-based treatment in practice","volume":"10","author":"Lucak","year":"2017","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"7","key":"10.1016\/j.pharmthera.2017.05.011_bb0540","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clinic Proceedings"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0545","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbadis.2004.11.011","article-title":"Roles of PPAR delta in lipid absorption and metabolism: A new target for the treatment of type 2 diabetes","volume":"1740","author":"Luquet","year":"2005","journal-title":"Biochimica et Biophysica Acta"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0550","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s11095-013-0986-7","article-title":"Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance","volume":"30","author":"Ma","year":"2013","journal-title":"Pharmaceutical Research"},{"issue":"5418","key":"10.1016\/j.pharmthera.2017.05.011_bb0555","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0560","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00018-003-3216-3","article-title":"Peroxisome proliferator-activated receptor alpha target genes","volume":"61","author":"Mandard","year":"2004","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.pharmthera.2017.05.011_bb0565","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.biochi.2016.11.010","article-title":"Roles of peroxisome proliferator-activated receptor \u03b2\/\u03b4 in skeletal muscle physiology","volume":"136","author":"Manickam","year":"2017","journal-title":"Biochimie"},{"issue":"Pt 3","key":"10.1016\/j.pharmthera.2017.05.011_bb0570","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1042\/BJ20041598","article-title":"Pregnenolone-16alpha-carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms","volume":"387","author":"Marek","year":"2005","journal-title":"The Biochemical Journal"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0575","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1128\/MCB.00927-09","article-title":"Hepatocyte nuclear factor 4alpha coordinates a transcription factor network regulating hepatic fatty acid metabolism","volume":"30","author":"Martinez-Jimenez","year":"2010","journal-title":"Molecular and Cellular Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0580","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cmet.2012.10.006","article-title":"Metabolomics identifies an inflammatory cascade involved in dioxin- and diet-induced steatohepatitis","volume":"16","author":"Matsubara","year":"2012","journal-title":"Cell Metabolism"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0585","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI200317223","article-title":"Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes","volume":"111","author":"Matsusue","year":"2003","journal-title":"The Journal of Clinical Investigation"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0590","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cmet.2008.03.003","article-title":"Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27","volume":"7","author":"Matsusue","year":"2008","journal-title":"Cell Metabolism"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0595","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0600","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1053\/j.gastro.2009.12.003","article-title":"Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection","volume":"138","author":"McHutchison","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0605","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/10408444.2015.1089471","article-title":"The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways","volume":"46","author":"Mellor","year":"2016","journal-title":"Critical Reviews in Toxicology"},{"issue":"46","key":"10.1016\/j.pharmthera.2017.05.011_bb0610","doi-asserted-by":"crossref","first-page":"35715","DOI":"10.1074\/jbc.M006577200","article-title":"Peroxisome proliferator-activated receptors and hepatic stellate cell activation","volume":"275","author":"Miyahara","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"issue":"7","key":"10.1016\/j.pharmthera.2017.05.011_bb0615","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0620","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jhep.2013.06.023","article-title":"Cell-specific PPAR\u03b3 deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells","volume":"59","author":"Mor\u00e1n-Salvador","year":"2013","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2017.05.011_bb0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsbmb.2015.04.011","article-title":"Environmental pollutants directly affect the liver X receptor alpha activity: Kinetic and thermodynamic characterization of binding","volume":"152","author":"Mozzicafreddo","year":"2015","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"issue":"50","key":"10.1016\/j.pharmthera.2017.05.011_bb0630","doi-asserted-by":"crossref","first-page":"34785","DOI":"10.1074\/jbc.M109.048108","article-title":"Dephosphorylation of threonine 38 is required for nuclear translocation and activation of human xenobiotic receptor CAR (NR1I3)","volume":"284","author":"Mutoh","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2017.05.011_bb0635","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejphar.2006.02.028","article-title":"Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet","volume":"536","author":"Nagasawa","year":"2006","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.05.011_bb0640","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbacli.2015.02.001","article-title":"Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy","volume":"3","author":"Nagaya","year":"2015","journal-title":"BBA Clinical"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0645","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s12328-008-0017-0","article-title":"Development from simple steatosis to liver cirrhosis and hepatocellular carcinoma: A 27-year follow-up case","volume":"1","author":"Nagaya","year":"2008","journal-title":"Clinical Journal of Gastroenterology"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0650","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2010.04.033","article-title":"Down-regulation of SREBP-1c is associated with the development of burned-out NASH","volume":"53","author":"Nagaya","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0655","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/hep.20399","article-title":"Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage","volume":"40","author":"Nakajima","year":"2004","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0660","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/mol.108.052928","article-title":"Bezafibrate at clinically relevant doses decreases serum\/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: A novel peroxisome proliferator-activated receptor alpha-independent mechanism","volume":"75","author":"Nakajima","year":"2009","journal-title":"Molecular Pharmacology"},{"issue":"29","key":"10.1016\/j.pharmthera.2017.05.011_bb0665","doi-asserted-by":"crossref","first-page":"22067","DOI":"10.1074\/jbc.M109.085118","article-title":"Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist","volume":"285","author":"Narala","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"issue":"9972","key":"10.1016\/j.pharmthera.2017.05.011_bb0670","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0675","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","article-title":"Identification of a novel FGF, FGF-21, preferentially expressed in the liver","volume":"1492","author":"Nishimura","year":"2000","journal-title":"Biochimica et Biophysica Acta"},{"issue":"12","key":"10.1016\/j.pharmthera.2017.05.011_bb0680","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.dld.2013.06.004","article-title":"Hepatitis B virus X protein co-activates pregnane X receptor to induce the cytochrome P450 3A4 enzyme, a potential implication in hepatocarcinogenesis","volume":"45","author":"Niu","year":"2013","journal-title":"Digestive and Liver Disease"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0685","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.bbalip.2005.08.009","article-title":"5-Oxo-ETE analogs and the proliferation of cancer cells","volume":"1736","author":"O'Flaherty","year":"2005","journal-title":"Biochimica et Biophysica Acta"},{"issue":"7","key":"10.1016\/j.pharmthera.2017.05.011_bb0690","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1248\/bpb.34.1120","article-title":"Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver","volume":"34","author":"Oishi","year":"2011","journal-title":"Biological & Pharmaceutical Bulletin"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0695","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jhep.2009.01.025","article-title":"Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress","volume":"50","author":"Okiyama","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"9","key":"10.1016\/j.pharmthera.2017.05.011_bb0700","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1073\/pnas.091021198","article-title":"A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport","volume":"98","author":"Oliver","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0705","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hep.25645","article-title":"Peroxisome proliferator-activated receptor alpha induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity","volume":"56","author":"Patterson","year":"2012","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.pharmthera.2017.05.011_bb0710","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2017.05.011_bb0715","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1388-1981(03)00065-9","article-title":"Bezafibrate is a dual ligand for PPARalpha and PPARbeta: Studies using null mice","volume":"1632","author":"Peters","year":"2003","journal-title":"Biochimica et Biophysica Acta"},{"issue":"11","key":"10.1016\/j.pharmthera.2017.05.011_bb0720","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1093\/carcin\/19.11.1989","article-title":"Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver","volume":"19","author":"Peters","year":"1998","journal-title":"Carcinogenesis"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0725","doi-asserted-by":"crossref","first-page":"G564","DOI":"10.1152\/ajpgi.00153.2014","article-title":"PPAR\u03b1-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate","volume":"307","author":"Qi","year":"2014","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0730","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/hep.22334","article-title":"Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice","volume":"48","author":"Qin","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0735","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jhep.2013.09.024","article-title":"Role of Myc in hepatocellular proliferation and hepatocarcinogenesis","volume":"60","author":"Qu","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0740","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jcb.10247","article-title":"Differential nuclear receptor signalling from DR4-type response elements","volume":"86","author":"Quack","year":"2002","journal-title":"Journal of Cellular Biochemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0745","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.bbrc.2012.11.027","article-title":"CCAAT\/enhancer binding protein \u03b2 deletion increases mitochondrial function and protects mice from LXR-induced hepatic steatosis","volume":"430","author":"Rahman","year":"2013","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0750","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.toxlet.2011.05.1034","article-title":"Aflatoxins upregulate CYP3A4 mRNA expression in a process that involves the PXR transcription factor","volume":"205","author":"Ratajewski","year":"2011","journal-title":"Toxicology Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0755","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0760","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"issue":"5745","key":"10.1016\/j.pharmthera.2017.05.011_bb0765","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/283397a0","article-title":"Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens","volume":"283","author":"Reddy","year":"1980","journal-title":"Nature"},{"issue":"4216","key":"10.1016\/j.pharmthera.2017.05.011_bb0770","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1198095","article-title":"Hepatic peroxisome proliferation: Induction by two novel compounds structurally unrelated to clofibrate","volume":"190","author":"Reddy","year":"1975","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0775","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408448309029317","article-title":"Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans","volume":"12","author":"Reddy","year":"1983","journal-title":"Critical Reviews in Toxicology"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0780","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm.2349","article-title":"A role for central nervous system PPAR-\u03b3 in the regulation of energy balance","volume":"17","author":"Ryan","year":"2011","journal-title":"Nature Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0785","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/clpt.2013.48","article-title":"Pregnane X receptor agonists impair postprandial glucose tolerance","volume":"93","author":"Rys\u00e4","year":"2013","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0790","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1023\/A:1021961919148","article-title":"Pathogenesis and pathophysiology of citrin (a mitochondrial aspartate glutamate carrier) deficiency","volume":"17","author":"Saheki","year":"2002","journal-title":"Metabolic Brain Disease"},{"issue":"9166","key":"10.1016\/j.pharmthera.2017.05.011_bb0795","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(05)75907-9","article-title":"Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis","volume":"353","author":"Saibara","year":"1999","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.pharmthera.2017.05.011_bb0800","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2017.05.011_bb0805","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/apt.13436","article-title":"Review article: The potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases","volume":"43","author":"Sartor","year":"2016","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"45","key":"10.1016\/j.pharmthera.2017.05.011_bb0810","doi-asserted-by":"crossref","first-page":"26746","DOI":"10.1074\/jbc.270.45.26746","article-title":"A novel serum protein similar to C1q, produced exclusively in adipocytes","volume":"270","author":"Scherer","year":"1995","journal-title":"The Journal of Biological Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0815","doi-asserted-by":"crossref","first-page":"G1114","DOI":"10.1152\/ajpgi.00528.2006","article-title":"Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression","volume":"292","author":"Shah","year":"2007","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"issue":"12","key":"10.1016\/j.pharmthera.2017.05.011_bb0820","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1128\/MCB.00317-07","article-title":"Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation","volume":"27","author":"Shah","year":"2007","journal-title":"Molecular and Cellular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0825","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/hep.21925","article-title":"Peroxisome proliferator-activated receptor-beta\/delta protects against chemically induced liver toxicity in mice","volume":"47","author":"Shan","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0830","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/toxsci\/kfn142","article-title":"Ligand activation of peroxisome proliferator-activated receptor beta\/delta (PPARbeta\/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression","volume":"105","author":"Shan","year":"2008","journal-title":"Toxicological Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0835","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1124\/dmd.32.1.66","article-title":"CYP3A induction by liver x receptor ligands in primary cultured rat and mouse hepatocytes is mediated by the pregnane X receptor","volume":"32","author":"Shenoy","year":"2004","journal-title":"Drug Metabolism and Disposition"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0840","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0378-1119(94)90080-9","article-title":"NER, a new member of the gene family encoding the human steroid hormone nuclear receptor","volume":"147","author":"Shinar","year":"1994","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0845","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e328333a1dd","article-title":"The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease","volume":"20","author":"Sookoian","year":"2010","journal-title":"Pharmacogenetics and Genomics"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0850","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bcp.2014.03.019","article-title":"Role of human pregnane X receptor in high fat diet-induced obesity in pre-menopausal female mice","volume":"89","author":"Spruiell","year":"2014","journal-title":"Biochemical Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0855","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1074\/jbc.M113.494575","article-title":"Role of pregnane X receptor in obesity and glucose homeostasis in male mice","volume":"289","author":"Spruiell","year":"2014","journal-title":"The Journal of Biological Chemistry"},{"issue":"6687","key":"10.1016\/j.pharmthera.2017.05.011_bb0860","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/31701","article-title":"Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators","volume":"393","author":"Staels","year":"1998","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0865","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.taap.2006.08.011","article-title":"In vitro screening of 200 pesticides for agonistic activity via mouse peroxisome proliferator-activated receptor (PPAR)alpha and PPARgamma and quantitative analysis of in vivo induction pathway","volume":"217","author":"Takeuchi","year":"2006","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0870","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/carcin\/bgq277","article-title":"Constitutive active\/androstane receptor promotes hepatocarcinogenesis in a mouse model of non-alcoholic steatohepatitis","volume":"32","author":"Takizawa","year":"2011","journal-title":"Carcinogenesis"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0875","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s00535-011-0370-5","article-title":"Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy","volume":"46","author":"Tanaka","year":"2011","journal-title":"Journal of Gastroenterology"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0880","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1572-0241.2007.01562_7.x","article-title":"Pancreatic exocrine insufficiency: A rare cause of nonalcoholic steatohepatitis","volume":"103","author":"Tanaka","year":"2008","journal-title":"The American Journal of Gastroenterology"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0885","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1478-3231.2005.01198.x","article-title":"Laparoscopic findings in patients with nonalcoholic steatohepatitis","volume":"26","author":"Tanaka","year":"2006","journal-title":"Liver International"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0890","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.25630","article-title":"Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis","volume":"56","author":"Tanaka","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0895","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ijc.23056","article-title":"Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor alpha in transgenic mice: Implications for HCV-associated hepatocarcinogenesis","volume":"122","author":"Tanaka","year":"2008","journal-title":"International Journal of Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0900","first-page":"683","article-title":"PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice","volume":"118","author":"Tanaka","year":"2008","journal-title":"The Journal of Clinical Investigation"},{"issue":"11","key":"10.1016\/j.pharmthera.2017.05.011_bb0905","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.bbalip.2014.08.015","article-title":"Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet","volume":"1841","author":"Tanaka","year":"2014","journal-title":"Biochimica et Biophysica Acta"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb0910","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1074\/jbc.M114.605980","article-title":"Adipocyte-specific disruption of fat-specific protein 27 causes hepatosteatosis and insulin resistance in high-fat diet-fed mice","volume":"290","author":"Tanaka","year":"2015","journal-title":"The Journal of Biological Chemistry"},{"issue":"7","key":"10.1016\/j.pharmthera.2017.05.011_bb0915","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.bbadis.2015.02.012","article-title":"Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet","volume":"1852","author":"Tanaka","year":"2015","journal-title":"Biochimica et Biophysica Acta"},{"issue":"8","key":"10.1016\/j.pharmthera.2017.05.011_bb0920","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1478-3231.2006.01338.x","article-title":"Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population","volume":"26","author":"Tanaka","year":"2006","journal-title":"Liver International"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0925","doi-asserted-by":"crossref","first-page":"A32","DOI":"10.1016\/j.cgh.2006.06.014","article-title":"A lean man with nonalcoholic fatty liver disease","volume":"5","author":"Tanaka","year":"2007","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0930","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1053\/j.gastro.2003.12.008","article-title":"Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met","volume":"126","author":"Tomita","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0935","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbrc.2004.09.110","article-title":"PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats","volume":"324","author":"Toyama","year":"2004","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0940","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s00535-009-0198-4","article-title":"Nonalcoholic fatty liver disease in Japanese junior high school students: Its prevalence and relationship to lifestyle habits","volume":"45","author":"Tsuruta","year":"2010","journal-title":"Journal of Gastroenterology"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0945","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/MCG.0b013e3181bdefe2","article-title":"Serum fragmented cytokeratin 18 levels reflect the histological activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels","volume":"44","author":"Tsutsui","year":"2010","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0950","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hep.20512","article-title":"Combined loss of orphan receptors PXR and CAR heightens sensitivity to toxic bile acids in mice","volume":"41","author":"Uppal","year":"2005","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0955","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1101\/gad.545110","article-title":"GPS2-dependent corepressor\/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRbeta in the hepatic acute phase response","volume":"24","author":"Venteclef","year":"2010","journal-title":"Genes & Development"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb0960","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tem.2009.03.003","article-title":"PXR and CAR in energy metabolism","volume":"20","author":"Wada","year":"2009","journal-title":"Trends in Endocrinology and Metabolism"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb0965","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(03)00269-1","article-title":"Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity","volume":"113","author":"Wang","year":"2003","journal-title":"Cell"},{"issue":"30","key":"10.1016\/j.pharmthera.2017.05.011_bb0970","doi-asserted-by":"crossref","first-page":"26913","DOI":"10.1074\/jbc.M111.248203","article-title":"Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure","volume":"286","author":"Watanabe","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"issue":"8","key":"10.1016\/j.pharmthera.2017.05.011_bb0975","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1073\/pnas.1200797109","article-title":"Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor \u03b3","volume":"109","author":"Wei","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb0980","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jhep.2013.07.044","article-title":"Pathological bacterial translocation in liver cirrhosis","volume":"60","author":"Wiest","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb0985","first-page":"407","article-title":"Pathway-based toxicity: History, current approaches and liver fibrosis and steatosis as prototypes","volume":"31","author":"Willett","year":"2014","journal-title":"ALTEX"},{"issue":"9","key":"10.1016\/j.pharmthera.2017.05.011_bb0990","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1101\/gad.9.9.1033","article-title":"LXR, a nuclear receptor that defines a distinct retinoid response pathway","volume":"9","author":"Willy","year":"1995","journal-title":"Genes & Development"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb0995","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2337\/db16-0663","article-title":"An intestinal farnesoid X receptor-ceramide signaling axis modulates hepatic gluconeogenesis in mice","volume":"66","author":"Xie","year":"2017","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb1000","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1053\/j.gastro.2015.06.009","article-title":"Fat-specific protein 27\/CIDEC promotes development of alcoholic steatohepatitis in mice and humans","volume":"149","author":"Xu","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb1005","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/hep.27371","article-title":"Transcriptional activation of Fsp27 by the liver-enriched transcription factor CREBH promotes lipid droplet growth and hepatic steatosis","volume":"61","author":"Xu","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb1010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/gut.2006.093260","article-title":"The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis","volume":"56","author":"Yamazaki","year":"2007","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb1015","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","article-title":"Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2017.05.011_bb1020","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12072-010-9202-6","article-title":"Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease","volume":"4","author":"Yang","year":"2010","journal-title":"Hepatology International"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb1025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.molmet.2013.04.001","article-title":"Adiponectin, driver or passenger on the road to insulin sensitivity?","volume":"2","author":"Ye","year":"2013","journal-title":"Molecular Metabolism"},{"issue":"3","key":"10.1016\/j.pharmthera.2017.05.011_bb1030","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/hep.27060","article-title":"Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1\u03b1-mediated antioxidant capacity in mice","volume":"60","author":"Ye","year":"2014","journal-title":"Hepatology"},{"issue":"41","key":"10.1016\/j.pharmthera.2017.05.011_bb1035","doi-asserted-by":"crossref","first-page":"23975","DOI":"10.1074\/jbc.270.41.23975","article-title":"Differential activation of peroxisome proliferator-activated receptors by eicosanoids","volume":"270","author":"Yu","year":"1995","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb1040","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1074\/jbc.M210062200","article-title":"Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression","volume":"278","author":"Yu","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb1045","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.23550","article-title":"Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro","volume":"51","author":"Yu","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2017.05.011_bb1050","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI59817","article-title":"Liver LXR\u03b1 expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice","volume":"122","author":"Zhang","year":"2012","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/j.pharmthera.2017.05.011_bb1055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/molbev\/msm251","article-title":"Analysis of nuclear receptor pseudogenes in vertebrates: How the silent tell their stories","volume":"25","author":"Zhang","year":"2008","journal-title":"Molecular Biology and Evolution"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb1060","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis","volume":"51","author":"Zhang","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"26","key":"10.1016\/j.pharmthera.2017.05.011_bb1065","doi-asserted-by":"crossref","first-page":"9406","DOI":"10.1073\/pnas.0501744102","article-title":"Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention","volume":"102","author":"Zhang","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/j.pharmthera.2017.05.011_bb1070","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.cellsig.2013.03.003","article-title":"MicroRNA-1 and microRNA-206 suppress LXR\u03b1-induced lipogenesis in hepatocytes","volume":"25","author":"Zhong","year":"2013","journal-title":"Cellular Signalling"},{"issue":"2","key":"10.1016\/j.pharmthera.2017.05.011_bb1075","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/j.gastro.2007.11.037","article-title":"Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis","volume":"134","author":"Zhou","year":"2008","journal-title":"Gastroenterology"},{"issue":"21","key":"10.1016\/j.pharmthera.2017.05.011_bb1080","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1074\/jbc.M511116200","article-title":"A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway","volume":"281","author":"Zhou","year":"2006","journal-title":"The Journal of Biological Chemistry"},{"issue":"11","key":"10.1016\/j.pharmthera.2017.05.011_bb1085","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1194\/jlr.M006486","article-title":"Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol","volume":"51","author":"Zhu","year":"2010","journal-title":"Journal of Lipid Research"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725817301304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725817301304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T19:13:29Z","timestamp":1750274009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725817301304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":217,"alternative-id":["S0163725817301304"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.05.011","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting nuclear receptors for the treatment of fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}